APTO News and Press, Aptose Biosciences Inc. From 04/27/19

Welcome to Seeking Alpha's Stocks to Watch - a preview of key events scheduled for the next week. Follow this account and turn the e-mail alert on to receive this article in your inbox every Saturday morning. The U.S. will send a high-level delegation to Beijing next week as trade negotiatio...

SAN DIEGO and TORONTO, April 24, 2019 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (NASDAQ: APTO; TSX: APS), a clinical-stage biotechnology company developing first-in-class agents that target the dysregulated processes and signaling pathways of cancer cells and address unmet medical needs o...

SAN DIEGO and TORONTO, April 23, 2019 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (NASDAQ: APTO; TSX: APS), a clinical-stage biotechnology company developing first-in-class agents that target the dysregulated processes and signaling pathways of cancer cells and address unmet medical needs o...

The following slide deck was published by Aptose Biosciences Inc. in conjunction with this Read more ...

Pan-FLT3/pan-BTK inhibitor CG-806 Demonstrates Significant and Superior Potency Against Primary Cells Across AML Types –   MYC Inhibitor APTO-253 Potently Kills Hematologic Cell Lines; Mechanism of Action Further Defined – SAN DIEGO and TORONTO, April 01, 2019 ...

The FDA has completed the review of Aptose Biosciences' (NASDAQ: APTO ) IND submission for CG-806. The Company has been granted IND allowance to initiate Phase 1 trial with expansions to assess the safety, tolerability, PK, and preliminary efficacy of CG-806 in patients with chro...

– CG-806 highly potent, oral, non-covalent pan-FLT3/pan-BTK inhibitor being developed for the treatment of CLL and other B-cell malignancies and for AML – – Phase 1 trial in relapsed or refractory CLL and B cell malignancies planned to initiate in Q2/2019 – ...

Aptose Biosciences Inc. (APTO) Q4 2018 Earnings Conference Call March 12, 2019 05:00 PM ET Company Participants Susan Pietropaolo - SMP Communications William Rice - Chairman, President, and CEO Gregory Chow - SVP and CFO Conference Call Participants Mathew Bilger - Oppenhe...

SAN DIEGO and TORONTO, March 07, 2019 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (Nasdaq: APTO; TSX: APS), a clinical-stage company developing highly differentiated therapeutics that target the underlying mechanisms of cancer, today announced that William G. Rice, Ph.D., Chairman, Presiden...

The Australian Patent Office has issued Aptose Biosciences (NASDAQ: APTO ) Patent No. 2013371146 for CG-806, a pan-FLT3/pan-BTK multi-cluster kinase inhibitor developed for acute myeloid leukemia (AML), B cell and other hematologic malignancies. This small molecule is in-licensed from Crys...